Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Marie-Josée Kravis Women ...